Using genetic and omics clues to find existing drugs that prevent atrial fibrillation from getting worse
Project 3 Genes to Omics-Informed Drugs: Drug Repositioning and Testing to Prevent AF Progressions
This project looks for already-approved medicines that could help people with atrial fibrillation stop their condition from progressing to more persistent forms.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11166617 on NIH RePORTER |
What this research studies
Researchers will analyze genes and other molecular (omics) data linked to atrial fibrillation progression to find key pathways and networks. They will use computational tools and AI to match those molecular signatures to drugs that might reverse or block the progression biology. Promising candidate drugs will be tested in laboratory models and human-derived samples to see if they prevent changes that lead to persistent AF. The aim is to repurpose safe, existing drugs so new treatments could reach patients faster.
Who could benefit from this research
Good fit: People with paroxysmal (intermittent) or recently diagnosed atrial fibrillation who are worried about progression to persistent AF are the main group this work targets.
Not a fit: Patients with long-standing permanent AF or those whose arrhythmia is driven entirely by reversible non-genetic causes may be less likely to benefit from these findings.
Why it matters
Potential benefit: Could identify existing, repurposable drugs that slow or prevent AF progression, potentially reducing the need for invasive procedures and lowering complication risks.
How similar studies have performed: Network-based drug-repurposing has shown promise in other diseases, but applying genomics-driven repurposing specifically to AF progression is relatively new and still emerging.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Chung, Mina Kay — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Chung, Mina Kay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.